VIENNA, July 20 /PRNewswire-USNewswire/ -- Following significant advances in vaccine and microbicide research, including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers' ability to quickly move promising approaches forward.
International Organizations Agree to Take Concerted Action to End Pediatric HIV/AIDS
"No child should enter this world infected with HIV."
VIENNA, Austria, July 19 /PRNewswire-USNewswire/ -- A global alliance of international organizations, including the heads of UNICEF, UNAIDS and The Global Fund to Fight AIDS, Tuberculosis and Malaria as well as other NGOs including the Pan African Treatment Access Movement, Health GAP, Ugandan Pediatric Association and the Global AIDS Alliance today agreed to take concerted action to eliminate pediatric HIV/AIDS over the next five years, preventing nearly 400,000 children annually from beginning their lives infected with the virus that causes AIDS.
"Every day, almost 1,000 babies are infected with HIV – and without diagnosis and treatment, half of these babies will not live to see th...
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
VIENNA, July 19 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients.
